home / stock / arct / arct news


ARCT News and Press, Arcturus Therapeutics Ltd. From 05/28/24

Stock Information

Company Name: Arcturus Therapeutics Ltd.
Stock Symbol: ARCT
Market: NASDAQ

Menu

ARCT ARCT Quote ARCT Short ARCT News ARCT Articles ARCT Message Board
Get ARCT Alerts

News, Short Squeeze, Breakout and More Instantly...

ARCT - Arcturus gains after early-stage data for cystic fibrosis therapy

2024-05-28 09:04:37 ET More on Arcturus Therapeutics Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earn...

ARCT - Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024 First four CF patients demonstrated an average improvement of 4% FEV1 after two administrations Arcturus Therapeutics Holdings Inc. (the “Company”, &#x...

ARCT - COVID-19 vaccine makers rebound amid post-pandemic prospects

2024-05-22 14:00:26 ET More on BioNTech, Moderna, etc. Pfizer: Offsetting The LOE Cliff Crisis With 6 New Potential Blockbuster Drugs Aggressive Strides Forward For Moderna's Cancer Vaccine Pfizer Stock: Rebound Has Started (Technical Analysis) Pfizer launchi...

ARCT - Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May...

ARCT - Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine PR Newswire Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These res...

ARCT - Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Earnings Call Transcript

2024-05-08 21:04:07 ET Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2024 Results Conference Call May 08, 2024 04:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations & Marketing. Joe Payne - President &...

ARCT - Arcturus Therapeutics GAAP EPS of -$1.00 beats by $0.23, revenue of $38M beats by $20.33M

2024-05-08 16:03:45 ET More on Arcturus Therapeutics Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis As more rare disease therapies launch, their prices are rising Seeking Alpha’s Quant Rating on Arcturus Therapeutics ...

ARCT - Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Commercial manufacture of Kostaive ® on track for delivery of initial 4 million doses in Q3 Kostaive ® European Marketing Authorization Application approval decision expected Q3 Multiple Kostaive ® Phase 3 trials further demonstrate breadth and durabilit...

ARCT - Expected US Company Earnings on Wednesday, May 8th, 2024

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

ARCT - Notable earnings after Wednesday's close

2024-05-07 17:35:59 ET Major earnings expected after the bell on Wednesday include: Energy Transfer LP ( ET ) Airbnb ( ABNB ) The Trade Desk ( TTD ) AMC Entertainment Holdings ( AMC ) Innovative Industrial Properties ( IIPR ) Read the full a...

Previous 10 Next 10